[Update on propofol TCI in children]

Area of Science:

• Anesthesiology
• Pharmacokinetics
• Pediatric Pharmacology

Context:

• Total intravenous anesthesia (TIVA) using propofol offers advantages in pediatric anesthesia.
• Current pharmacokinetic (PK) models for TCI in children are limited, often relying solely on weight and exhibiting high variability.
• Physiological covariates like age and lean body mass are increasingly recognized as important for pediatric PK/PD models.

Purpose:

• To review the challenges and advancements in developing pediatric pharmacokinetic (PK) and pharmacodynamic (PD) models for propofol TCI.
• To evaluate the potential adaptation of adult models, such as Schnider et al.'s, for use in pediatric populations over 5 years old.
• To highlight the need for PK/PD models specifically validated for pediatric anesthesia.

Summary:

• Existing pediatric propofol PK models, primarily weight-based, show significant interindividual variability.
• Incorporating physiological covariates is essential for accurate modeling during pediatric growth and maturation.
• No definitive PK/PD model currently exists for pediatric anesthesia, though adult models may be adaptable for older children.

Impact:

• Improved accuracy in propofol dosing for pediatric patients undergoing TIVA.
• Enhanced understanding of propofol's PK/PD in children, leading to safer anesthesia practices.
• Potential for reduced interindividual variability in anesthetic response through model refinement and pharmacodynamic monitoring.